Moleac is excited to announce a significant milestone in the journey of NeuroAiD II MLC901 as đŁđ§ đđ˛đżđżđźđť đŁđŽđż đŁđľđŽđżđşđŽđ°đ˛đđđśđ°đŽđšđ will become our exclusive partner in Indonesia effective Jan 1ˢáľÂ 2025.
We are immensely grateful for the fruitful 12-year partnership with PT Mersifarma Tirmaku Mercusana, and we sincerely thank them for their invaluable contributions to our success in Indonesia. As we embark on a new chapter, we are thrilled to welcome PT Ferron Par Pharmaceuticals â a member of Dexa Group â as our new exclusive commercial partner.
This partnership marks a crucial milestone in our mission to widen access to our groundbreaking products, supporting healthcare professionals in enhancing outcomes for patients recovering from stroke, traumatic brain injuries, and neurodegenerative diseases.
With PT Ferron Par Pharmaceuticals, a leader renowned for its market expertise and operational excellence, we are confident in our accelerated growth and the expanded availability of NeuroAiD II MLC901 to those in need.
We look forward to a future of growth and continued innovation as we extend the reach of NeuroAiD II MLC901 in Indonesia to benefit more patients.
Access to the full press release here:Â https://www.prnewswire.com/news-releases/moleac-announces-pt-ferron-par-pharmaceuticals-as-new-exclusive-partner-in-indonesia-302281877.html
